Health technology assessment has been developing rapidly in Asia, but the requirements for pharmacoeconomics evidence vary across countries, from well-defined in some countries to not well established and vague in other countries. This forum serves participants to understand the new requirements and to promote the collaborations among different key stakeholders. This forum will provide an overview and case studies of these new developments in China, Japan, South Korea and Taiwan, specifically in the following areas: 1) Is HTA/cost-effectiveness nice-to-have or must have? If yes, what are the evidence requirements outside of clinical trials?; 2) Insights into local “requirements” versus accepted pragmatic approaches; 3) Close collaborations and proactive dialogues across Asia among government HTA (or HTA alike) agencies, regulatory agencies, academics, the pharma (and medical device as well) industry, health care providers and patients groups; 4) The utilization of real-world data to support the decision making.